Skip to main content

Significant itch relief and nodule clearance in PN

Studied in two 24-week pivotal trials in adults—PRIME AND PRIME21,2

PRIME (18+ years)

≈3x

EXPERIENCED ITCH RELIEF

Proportion of patients with ≥4-point reduction in WI-NRS at Week 24: 60% with DUPIXENT vs 18% with placebo (P<0.001, primary endpoint)1,2

PRIME2 (18+ years)

Significant itch reduction was achieved by 37% of DUPIXENT patients at Week 12 vs 22% with placebo (P=0.022, primary endpoint) and 58% vs 20% of patients, respectively, at Week 24 (P<0.001, secondary endpoint)1,2

ITCH DATA
PRIME (18+ years)

≈2.5x

ACHIEVED NODULE CLEARANCE

Proportion of patients achieving IGA PN-S 0 or 1 at Week 24: 48% with DUPIXENT vs 18% with placebo (P<0.001, secondary endpoint)1,2

PRIME2 (18+ years)

Significant nodule clearance was achieved by 45% of DUPIXENT patients at Week 24 vs 16% with placebo (P<0.001, secondary endpoint)1,2

NODULE CLEARANCE DATA

Demonstrated safety profile1

Most common adverse reactions in patients with prurigo nodularis (incidence ≥2%) are nasopharyngitis, conjunctivitis, herpes infection, dizziness, myalgia, and diarrhea.
SAFETY DATA

Watch healthcare providers discuss why they choose DUPIXENT

PEER VIDEOS

IGA PN-S, Investigator’s Global Assessment PN-
Stage; PN, prurigo nodularis; WI-NRS, Worst Itch numerical rating scale.